Pezadeftide
Hexima is conducting a phase IIb clinical trial of its lead antifungal molecule, pezadeftide (previously HXP124), as a potential topical treatment for fungal nail infections (onychomycosis).
KOL Interviews
Hexima recently took the opportunity to speak with certain of its Scientific Advisory Board members about Onychomycosis. We captured these interactions, which are available for viewing.
Investor Webinar Recording
NailMail Newsletter: Q3 2021
Thanks to those who joined our Investor Review Webinar held on 8 Sept 2021. A full recording is now available by clicking the link below.
NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.
Investor Webinar Recording
Thanks to those who joined our Investor Review Webinar held on 8 Sept 2021. A full recording is now available by clicking the link below.
NailMail Newsletter: Q3 2021
External Links
Take a look at these useful links to learn more about our industry.
